Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Status:
Completed
Trial end date:
2015-05-27
Target enrollment:
Participant gender:
Summary
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of
bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase
Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one
year.